The current DMD therapy can be divided into approaches targeting dystrophin restoration and those aimed at reducing the secondary consequences of dystrophin absence, i.e., a prolonged inflammatory response and the consequent activation of the immune system. This evidence concerns the gene DMD and Duchenne muscular dystrophy.